We are thrilled to announce that RitSight, our 0.22% riboflavin ophthalmic solution for corneal cross-linking, has been granted the CE Certificate in conformity with the Medical Device Regulation (MDR)! This certification marks a significant step forward ...
The Regensight's Theranostics (a new paradigm of therapy guided by diagnostics), is going to halt keratoconus progression with certainty. Keratoconus is primary cause of corneal transplant in young adults worldwide (prevalence: 1% - 2%, about 100 mil ...
The Regensight team has been an active part of The European Society of Cataract and Refractive Surgery (ESCRS) International Conference, which was held in Vienna from 8 to 11 September 2023.At the startup's stand, the Team has allowed the eye surgeons to ...
